3.1. Clinical indicators
tumor necrosis, psoriasis
SYNDROME, TUMOR NECROSIS, YANG DEFICIENCY, PSORIASIS
Ninety-two participants with a diagnosis of PS were recruited from July 2019 to August 2021. There were no significant differences between the 2 groups at the baseline (Table Baseline clinical characteristics and governor vessel moxibustion (GVM) treatment effects of study participants in the blank and GVM groups.Independent samples DLQI = dermatology life quality index, GVM = governor vessel moxibustion, IFN-γ = interferon gamma, IL = interleukin, NA = not applicable, PASI = psoriasis area and severity index, s = scores, SD = standard deviation, TNF-α = tumor necrosis factor alpha, YDSS = Yang deficiency syndrome score, yr = years.